May 2026– date –
-
Viral Vector Manufacturing Market Projected to Reach USD 12.84 Billion by 2036: Driven by Gene Therapy Advances and CDMO Role
OpenPR Global Overview This article provides an overview of a market research report distributed by OpenPR. The report forecasts that the global viral vector manufacturing market will reach USD 12.84 billion by 2036, driven by the increa... -
EktaH Reveals Promising Early-Phase Data for Novel Obesity Drug NKS-3, Targeting Fat Loss with Muscle Retention
European Biotechnology Global Overview EktaH has released early clinical trial data for its novel obesity drug candidate, NKS-3, demonstrating promising results in both fat reduction and muscle preservation. Preclinical mouse data indica... -
Eli Lilly’s Oral Orforglipron Effective in Older Adults with Obesity, Receives FDA Approval as Non-Peptide GLP-1 Offering Dosing Flexibility
Medscape USA Overview Eli Lilly's once-daily oral GLP-1 receptor agonist, orforglipron (Foundayo), demonstrated clinically significant weight loss and a favorable safety profile in obese adults aged 65 and older, similar to younger popul... -
Precision Peptide Company (BPC) Pioneers Advanced Peptide Manufacturing with Continuous Flow Synthesis and AI Integration to Meet GLP-1 Demand
Bitget アイルランド Overview Precision Peptide Company Inc. (BPC) is emerging as a critical CDMO partner for GLP-1 agonists, oncology vaccines, and targeted radiopharmaceuticals. Their proprietary "Flow-Peptide" continuous flow synthesis... -
Novo Nordisk’s CagriSema Achieves Over 22% Weight Loss in Phase 3 Trials: Synergistic Benefits of GLP-1 and Amylin Analog
Life Science Daily News Global Overview Novo Nordisk's CagriSema, a combination therapy featuring a GLP-1 receptor agonist and the amylin analog cagrilintide, demonstrated over 22% weight reduction in Phase 3 trials. Specifically, the RE... -
Divi’s Labs: The ‘TSMC of Pharma’ for Peptides? GLP-1 Demand Elevates Manufacturing to Strategic Imperative
Antifragile Thinking Global Overview The surging global demand for GLP-1 therapeutics has transformed peptide manufacturing into one of the most strategically critical areas within the CDMO sector. India's Divi's Labs stands out as a key... -
Small Molecule Drug CDMO Market Sees Strong Growth, Driven by HPAPI and Continuous Manufacturing; WuXi AppTec Leads
OpenPR Global Overview The small molecule drug CDMO market is experiencing robust growth, fueled by increased outsourcing from pharmaceutical and biotech companies. Key drivers include investments in specialized facilities for highly pot... -
The Modern CDMO: A Strategic Blueprint for Pharmaceutical Leaders in a Complex Era
Agnopharma Global Overview This guide outlines the evolution of CDMOs from traditional CMOs, emphasizing their indispensable role in contemporary drug development. Modern CDMOs offer integrated solutions from process development to comme... -
GLP-1 Drug Manufacturing: Global Capacity Expansion and Tech Transfer Accelerate to Meet Soaring Demand
IntuitionLabs Global Overview The unprecedented surge in demand for GLP-1 therapeutics is driving a rapid global expansion of manufacturing capacity and technology transfer strategies in the pharmaceutical industry. Novo Nordisk is inves... -
Zealand Pharma Advances Obesity Pipeline with Phase 3 Progress, Leveraging Roche and Boehringer Ingelheim Partnerships
WhaleWisdom Global Overview Zealand Pharma, in partnership with Roche, is progressing its obesity drug candidate petrelintide into Phase 3 trials following favorable Phase 2 data on weight loss and tolerability. Separately, Boehringer In...
